Events

DM Intelligence Ltd. Brings AI New Drug Development Project to Shanghai

May, 16, 2019

When AlphaGo defeated South Korea's Li Shishi and swept all the players in the entire world of Go, the AI Go player who was born in the world suddenly became famous all over the world. For a time, people's eyes turned to the field of artificial intelligence. In fact, artificial intelligence is not unfamiliar to everyone, but it has always been tepid. Because the AlphaGo battle of Go is invincible, artificial intelligence is brought back to everyone's field of vision. 2017 is the first year of artificial intelligence explosion. The products of AI+ are constantly appearing in our lives. From the unmanned driving and face recognition, it shows the infinity of artificial intelligence.

Looking at the pharmaceutical industry, the development of a new drug has been very difficult. According to data from the Taft Center for Drug Development Research, it takes an average of 96.8 months (8 years) for a new drug to be available from drug discovery to FDA approval. In terms of cost, Deloitte data shows that since 2010, the cost of approved drug development for 12 major pharmaceutical companies has increased by 33%, about $1.6 billion per year. In general, the new drug development cycle is long, the investment is large, the efficiency is low, and the drug correct rate is low.

With the rise of artificial intelligence, AI+ new drug research and development has become the focus of more and more people. So what are the AI technologies that can be applied to the development of new drugs?

1. Confirmation of drug targets

2. Construction of novel compounds

3. Multiple screening of active compounds

4. Drug effectiveness/safety prediction

5. Development of preparations, etc.

Because AI technology has such a large role in promoting the development of new drugs, many new drug research and development companies with AI as the platform have sprung up, and have also received the attention and attention of many investors.

(Source: due to data, network public data)

As can be seen from the above table, China's medical development in recent years is very fast, from less than 10 billion yuan in 2016 to about 20 billion yuan in 2018. The compound annual growth rate is over 40%, and the forecast is 2020. In the year, the total market size of artificial intelligence in China will exceed 40 billion yuan. It can be said that the application of domestic artificial intelligence in the medical field has a very large development space for the new drug research and development market.

The research and development of new drugs by DM Intelligence Ltd. is also based on artificial intelligence, mainly focusing on small molecules. At this stage, DM Intelligence Ltd. has its own independent AI R&D platform and independent database backend as technical support. Our original intention is to make new drugs in the true sense based on the effectiveness of the target and the innovation of the platform.

(Dr. Xie Weidong, CEO of DM Intelligence Ltd., gave a speech)

(Dr. Xie Weidong, CEO of DM Intelligence Ltd., gave a speech)

Recently, Dr. Xie Weidong, CEO of DM Intelligence Ltd., gave a speech on the company's AI new drug research and development project at the 5th BFC Medical Health Industry Business Development and Investment Cooperation Conference held at JW Marriott Hotel Shanghai. At the meeting, Dr. Xie introduced in detail the relationship between AI and the new drug research and development platform, as well as the development and scale of the platform at the current stage, which attracted the attention of many people at the venue. After the speech, Dr. Xie had an in-depth exchange with many participants, in order to seek mutual guidance, learn from each other and promote each other.

(speech scene)

Although the young field of AI+ new drug development is still very long, the future of the industry will certainly play a pivotal role in the medical industry.